Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

33.59

Margin Of Safety %

Put/Call OI Ratio

0.18

EPS Next Q Diff

-0.02

EPS Last/This Y

0.86

EPS This/Next Y

-0.29

Price

6.86

Target Price

22.25

Analyst Recom

1.22

Performance Q

Relative Volume

0.52

Beta

0.19

Ticker: ALT




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19ALT8.180.230.29150080
2024-12-20ALT8.270.230.09150744
2024-12-23ALT7.770.190.43126097
2024-12-24ALT7.680.190.27130194
2024-12-26ALT8.020.190.49131979
2024-12-27ALT7.660.190.65135770
2024-12-30ALT7.320.200.19130728
2024-12-31ALT7.220.200.14138266
2025-01-02ALT7.110.200.28144107
2025-01-03ALT7.280.200.51149955
2025-01-06ALT7.260.200.18149879
2025-01-07ALT7.320.200.17152548
2025-01-08ALT7.450.200.13154351
2025-01-09ALT7.450.200.12154351
2025-01-10ALT6.860.200.20156776
2025-01-13ALT6.770.190.11155319
2025-01-14ALT6.230.190.30156414
2025-01-15ALT6.590.190.12158146
2025-01-16ALT6.720.180.27160257
2025-01-17ALT6.860.180.27161966
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19ALT8.18173.0-41.7-0.80
2024-12-20ALT8.27173.0-37.3-0.80
2024-12-23ALT7.76173.0-24.3-0.80
2024-12-24ALT7.55173.0-30.3-0.80
2024-12-26ALT8.00173.0-46.4-0.80
2024-12-27ALT7.66173.0-27.5-0.80
2024-12-30ALT7.32173.0-27.1-0.80
2024-12-31ALT7.22173.0-32.8-0.80
2025-01-02ALT7.12173.0-33.0-0.80
2025-01-03ALT7.27173.0-39.7-0.80
2025-01-06ALT7.25173.0-35.2-0.80
2025-01-07ALT7.32173.0-37.1-0.80
2025-01-08ALT7.45173.0-38.9-0.80
2025-01-09ALT7.45173.0-35.3-0.80
2025-01-10ALT6.86173.0-20.5-0.80
2025-01-13ALT6.77173.0-32.6-0.80
2025-01-14ALT6.22173.0-19.5-0.80
2025-01-15ALT6.58173.0-46.9-0.80
2025-01-16ALT6.71173.0-39.5-0.80
2025-01-17ALT6.86173.0-39.9-0.80
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19ALT-2.64-6.7533.23
2024-12-20ALT-2.64-6.7533.23
2024-12-23ALT-2.62-6.7433.23
2024-12-24ALT-2.62-6.7433.23
2024-12-26ALT-2.71-6.7433.82
2024-12-27ALT-2.64-6.7433.82
2024-12-30ALT-2.75-6.7333.82
2024-12-31ALT-2.75-6.7333.82
2025-01-02ALT-2.68-6.7333.82
2025-01-03ALT-2.64-6.7333.82
2025-01-06ALT-2.59-6.6633.82
2025-01-07ALT-2.59-6.6633.82
2025-01-08ALT-2.64-6.6633.82
2025-01-09ALT-2.64-6.6633.82
2025-01-10ALT-2.64-6.6633.82
2025-01-13ALT-2.61-6.6033.59
2025-01-14ALT-2.61-6.6033.59
2025-01-15ALT-2.61-6.6033.59
2025-01-16ALT-2.61-6.6033.59
2025-01-17ALT-2.61-6.6033.59
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.32

Avg. EPS Est. Current Quarter

0.24

Avg. EPS Est. Next Quarter

-0.34

Insider Transactions

-2.61

Institutional Transactions

-6.6

Beta

0.19

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

24

Growth Score

32

Sentiment Score

16

Actual DrawDown %

80.5

Max Drawdown 5-Year %

-93.6

Target Price

22.25

P/E

Forward P/E

PEG

P/S

9758.38

P/B

3.66

P/Free Cash Flow

EPS

-1.55

Average EPS Est. Cur. Y​

-0.8

EPS Next Y. (Est.)

-1.09

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-199076.92

Relative Volume

0.52

Return on Equity vs Sector %

-96.7

Return on Equity vs Industry %

-84.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-39.9
Altimmune, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 59
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
stock quote shares ALT – Altimmune, Inc. Stock Price stock today
news today ALT – Altimmune, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALT – Altimmune, Inc. yahoo finance google finance
stock history ALT – Altimmune, Inc. invest stock market
stock prices ALT premarket after hours
ticker ALT fair value insiders trading